Update on therapy for osteoporosis

Orthopaedic Nursing

Volumn 26, Issue 3, 2007, Pages 162-166

  Licata, Angelo A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT;

DECISION MAKING; FEMALE; HUMAN; MALE; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

BONE DENSITY CONSERVATION AGENTS; DECISION MAKING; FEMALE; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 34249816131     PISSN: 07446020     EISSN: 1542538X     Source Type: Journal    
DOI: 10.1097/01.NOR.0000276965.00399.9e     Document Type: Review

References (20)

1. Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J.A., Thompson, D.E., Nevitt, M.C., et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348, 1535-1541.
2. Bogoch, E. R., Elliot-Gibson, V., Beaton, D. E., Jamal, S. A., Josse, R. G., & Murray, T. M. (2006). Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopedic environment. Journal of Bone and Joint Surgery, 88, 25-34.
3. Brankin, E., Walker, M., Lynch, N., Aspray, T., Lis, Y., & Cowell, W. (2006). The impact of dosing frequency on compliance and persistence with the bisphosphonates among postmenopausal women in the UK: Evidence from three databases. Current Medical Research and Opinion, 22, 1249-1256.
4. Carnevale, V., Nieddu, L., Romagnoli, E., Bona, E., Piedmonte, S., Scillitani, A., et al. (2006). Osteoporosis intervention in ambulatory patients with previous hip fractures: A multicentric, nationwide Italian survey. Osteoporosis International, 17, 478-483.
5. Cefalu, C. A. (2004). Is bone mineral density predictive of fracture risk reduction? Current Medical Research and Opinion, 20(3), 341-349.
6. Chesnut, C. H., Silverman, S., Andriano, K., Genant, H.K., Gimona, A., Harris, S., et al. (2000). A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures Study. PROOF Study Group. American Journal of Medicine, 109, 267-276.
7. Cummings, S. R., Black, D. M., Thompson, D. E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., et al. (1998). Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. Journal of the American Medical Association, 280, 2077-2082.
8. Ensrud, K., Genazzani, A. R., Geiger, M. J., McNabb, M., Dowsett, S. A., Cox, D. A., et al. (2006). Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. American Journal of Cardiology, 97, 520-527.
9. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R.K., Nickelsen, T., Genant, H.K., et al. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Journal of the American Medical Association, 282, 637-645.
10. Harris, S. T., Watts, N. B., Jackson, R. D., Genant, H.K., Wasnich, R.D., Ross, P., et al. (1993). Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. American Journal of Medicine, 95, 557-567.
11. Harris, S. T., Watts, N. B., Genant, H. K., McKeever, C.D., Hangartner, C.D., Keller, M., et al. (1999). Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy [VERT] Study Group. Journal of the American Medical Association, 282, 1344-1352.
12. Khosla, S., & Kleerekorper, M. (2003). Biochemical markers of bone turnover. In Favus, M. J. (ed.), Primer on metabolic bone diseases and disorders of mineral metabolism (5th ed.) (pp. 166-172). Washington, DC: American Society for Bone and Mineral Research, 2003.
13. Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Pruce, R., Gaich, G.A., Reginster, J., et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344, 1434-1441.
14. Ostrzenski, A., & Istrzenska, K. M. (2005). WHI clinical trial revisit: Imprecise scientific methodology disqualifies the study's outcomes. American Journal of Obstetrics and Gynecology, 193, 1599-1604.
15. Reginster, J., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., et al. (2000). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International, 11, 83-91.
16. Seeman, E., & Delmas, P. D. (2006). Bone quality - the material and structural basis of bone strength and fragility. New England Journal of Medicine, 354, 2250-2261.
17. Siris, E., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., et al. (2006). Adherence to bisphosphonate therapy and fractures rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims data bases. Mayo Clinical Proceedings, 81, 1009-1012.
18. Solomon, D. H., Brookhart, M. A., Gandhi, T. K., Karson, A., Gharib, S., Orav, E. J., Shaykevich, S., et a. Adherence with osteoporosis practice guidelines: A multilevel analysis of patient, physician, and practice setting characteristics. American Journal of Medicine, 117, 919-924.
19. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., et al. (2006). Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial [online journal]. Journal of the American Medical Association, 295, E1-E15.
20. Writing group for the Women's Health Initiative investigators. (2002). Risk and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321-333.